Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT06934057
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
  • Cabozantinib — DRUG
    Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.

Study Details

The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer

Key Dates

Start date
May 16, 2025
Status verified
Sep 2025
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib-Nivolumab
    The patient will be treated according to standard of care Nivolumab Cabozantinib.

Primary Outcome Measure

Starting dose of Cabozantinib [ Time Frame: 24 weeks after treatment start ]

Central Contacts

Related Studies